Standing Desks May Not Be The Silver Bullet We Thought

You might want to sit down for this.

Health & Lifestyle
221

Listen to article (english)

Translate to Spanish or other 102 languages!

Standing more doesn’t improve heart health compared to sitting, and after as little as 2 hours, it might actually harm you. Image for illustration purposes
Standing more doesn’t improve heart health compared to sitting, and after as little as 2 hours, it might actually harm you. Image for illustration purposes

Medical News Today

- Advertisement -

If you, like me, have invested in a standing desk, new research from the University of Sydney may challenge an established idea about workplace wellness. After analyzing data from 83,000 adults, researchers uncovered something surprising: Standing more doesn’t improve heart health compared to sitting, and after as little as 2 hours, it might actually harm you.

Follow the link below to read the full story on Medical News Today:

https://www.medicalnewstoday.com/articles/can-standing-too-much-harmful-heart-health-sitting?utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=sundaysupplement&utm_content=2024-10-27&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
New Stroke Prevention Guidelines Highlight Lifestyle Changes
Next article
A Journey into Ultrasound Technology

More Articles

FDA Authorizes First Wearable Device that Continuously Monitors Both Ketone Levels and Blood Sugar

The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.

Golden Years, Restless Nights: How Aging Transforms Your Sleep Cycles

If you have trouble falling asleep or staying asleep, your age could be playing a role.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral’s Webinar on Suicide Prevention Awareness, Sept. 3rd

More than 49,000 people died by suicide in the United States in 2023, according to the Centers for Disease Control and Prevention (CDC), making it one of the leading causes of death among adolescents and adults.
- Advertisement -